ATAI LIFE SCIENCES NV (ATAI) Stock Price, Quote, News and Overview
NASDAQ:ATAI - Nasdaq - NL0015000DX5 - Common Stock - Currency: USD
ATAI Quote, Performance and Key Statistics
ATAI LIFE SCIENCES NV
NASDAQ:ATAI (2/12/2025, 8:00:00 PM)
Premarket: 2.26 -0.29 (-11.37%)2.55
+0.32 (+14.35%)
The current stock price of ATAI is 2.55 USD. In the past month the price increased by 91.73%. In the past year, price increased by 38.59%.
ATAI Latest News and Analysis
Wondering what's happening in today's after-hours session?
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
atai Life Sciences Announces Pricing of Public Offering of Common Shares
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences Announces Proposed Public Offering of Common Shares
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
ATAI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.15 | 828.73B | ||
| JNJ | JOHNSON & JOHNSON | 15.54 | 373.81B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 25.72 | 363.16B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.62 | 230.81B | ||
| MRK | MERCK & CO. INC. | 11.21 | 216.71B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.65 | 213.92B | ||
| PFE | PFIZER INC | 8.19 | 144.34B | ||
| SNY | SANOFI-ADR | 13.71 | 136.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 49.25 | 113.88B | ||
| ZTS | ZOETIS INC | 30.19 | 78.45B | ||
| GSK | GSK PLC-SPON ADR | 7.8 | 73.71B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.14 | 42.04B |
Related stock screener links
About ATAI
Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Berlin, Berlin and currently employs 83 full-time employees. The company went IPO on 2021-06-18. The firm engages in developing various treatments that focuses on various mental health disorders. The firm's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Company Info
ATAI LIFE SCIENCES NV
Wallstrasse 16
Berlin BERLIN 100022 DE
CEO: Florian Brand
Employees: 83
Company Website: https://atai.life/
Investor Relations: https://ir.atai.life/
Phone: 498921539035
ATAI FAQ
What is the stock price of ATAI?
The current stock price of ATAI is 2.55 USD.
What is the symbol for ATAI LIFE SCIENCES NV stock?
The exchange symbol of ATAI LIFE SCIENCES NV is ATAI and it is listed on the Nasdaq exchange.
On which exchange is ATAI stock listed?
ATAI stock is listed on the Nasdaq exchange.
Is ATAI a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ATAI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ATAI.
Does ATAI stock pay dividends?
ATAI does not pay a dividend.
What is the Price/Earnings (PE) ratio of ATAI?
ATAI does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
What is the Short Interest ratio of ATAI stock?
The outstanding short interest for ATAI is 7.65% of its float.
ATAI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 93.21% of all stocks.
ATAI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATAI. The financial health of ATAI is average, but there are quite some concerns on its profitability.
ATAI Financial Highlights
Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by -80% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.11% | ||
| ROE | -88.25% | ||
| Debt/Equity | 0.14 |
ATAI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ATAI. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -189.82% and a revenue growth 21.83% for ATAI